ArticleFEBS open bio2025
Two-way inhibition of PAX5 transcriptional activity by PAX5::CBFA2T3.
Article in FEBS open bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
PAX5 promotes B-cell differentiation by transcriptional activation of B-lineage-specific genes. Chromosomal rearrangements in PAX5 account for 2-3% of B-ALL cases, and most lead to the expression of in-frame fusion transcripts. These fusions can encode chimeric proteins composed of the N-terminal portion of PAX5 and the C-terminal region of a variety of heterogeneous fusion partners. We analyzed the function of PAX5::CBFA2T3 (PAX5-C), a fusion protein found in B-cell acute lymphoblastic leukemia. PAX5-C strongly repressed PAX5 transcriptional activity in luciferase assays. In co-immunoprecipitation assays, PAX5-C bound to PAX5 and HDAC1/3. However, neither HDAC knockdown nor treatment with a HDAC inhibitor showed any effect on the repression of PAX5 transactivity by PAX5-C. In addition, PAX5-C with DNA binding-defective mutations (PAX5 M-C) could still repress PAX5 transactivity; however, the repression of PAX5 transactivity by PAX5 M-C was abolished by inhibition or knockdown of HDAC. These findings indicate that PAX5-C exhibits two mechanisms of repression: a DNA binding-dependent and a HDAC-dependent mechanism, with either being sufficient for the repression of PAX5 transactivity by PAX5-C. We performed ChIP-qPCR under conditions of the luciferase assay and inferred that these two mechanisms involved the inhibition of direct binding of PAX5 to the promoter due to promoter occupancy by PAX5-C, and recruitment of HDAC1/3 to the PAX5 transcription complex by the binding of PAX5-C to PAX5 on the promoter. The present results provide novel insight into the mechanisms of how PAX5-fusion proteins inhibit PAX5 function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.